Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $6.6552W HIGH $36.26
Volume
758.25 K
Value Traded
8.63 M
Short % Float
22.86%
-5.21%Week
-26.85%1 Month
-34.01%3 Month
-50.91%6 Month
-46.56%5 Year
-69.6%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
684.23 M
EPS (TTM)
-2.34
P/E Ratio
-
Ent. Value
223.16 M
Total Shares
87.50 M
Float Shares
70.29 M
Insiders
19.66%
Institutions
99.97%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
OLMA Catalyst Timeline
Dated clinical, regulatory and corporate events for Olema Pharmaceuticals, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Olema Pharmaceuticals, Inc.
305Total events
10Upcoming
29Tier-1 (high impact)
2020 to 2029Coverage
Upcoming catalysts 2
Event history 50
●Equity OfferingCorporate
Inducement stock options granted to six new employees (235,950 shares)
▲Partnership / LicenseCorporate
Announced a clinical trial collaboration and supply agreement with Bayer
◆Poster PresentationPalazestrantPresentation
Trial-in-progress poster for OPERA-02 at ASCO 2026
ER+/HER2- metastatic breast cancersource ↗
●Oral PresentationOP-3136Presentation
Presented initial Phase 1 clinical data for OP-3136 at the 2026 ASCO Annual Meeting
◆Poster PresentationOP-3136Presentation
Initial clinical data for OP-3136 poster presentation at ASCO 2026
advanced solid tumors; ER+, HER2- advanced breast cancersource ↗
◆Topline ReadoutOP-3136Clinical Data
Preliminary Phase 1 data for OP-3136 (data cut-off March 2, 2026)
advanced solid tumorssource ↗
▲Partnership / LicenseOP-3136Corporate
Clinical trial collaboration and supply agreement with Bayer to evaluate OP-3136 in combination with darolutamide
metastatic castration-resistant prostate cancersource ↗
◆Oral PresentationOP-3136Presentation
Initial clinical data from Phase 1 study of OP-3136 presented at ASCO
ER+/HER2- breast cancersource ↗
●Poster PresentationPalazestrantPresentation
Trial-in-progress poster for OPERA-02 at ASCO
ER+/HER2- metastatic breast cancersource ↗
◆Poster PresentationPalazestrantPresentation
Poster presentation on palazestrant NCoR1 recruitment mechanism at AACR 2026
ER+/HER2- breast cancersource ↗
●Poster PresentationOP-3136Presentation
Poster presentation: Palazestrant in combination with OP-3136 synergistically downregulates cell proliferation and metastasis gene signatures
ER+ metastatic breast cancersource ↗
◆Trial InitiationOP-3136Trial
Phase 1b/2 study of OP-3136 in combination with darolutamide expected to initiate
metastatic castration-resistant prostate cancersource ↗
▲Poster PresentationPalazestrantPresentation
Preclinical poster at AACR 2026 demonstrating NCoR1 recruitment
ER+/HER2- breast cancersource ↗
◆Topline ReadoutOP-3136Clinical Data
Initial clinical results for OP-3136
breast cancer and other solid tumorssource ↗
●Enrollment UpdatePalazestrantTrial
Advanced enrollment in Phase 1b/2 study with atirmociclib
ER+/HER2- metastatic breast cancersource ↗
◆Oral PresentationPresentation
Olema Oncology to present at TD Cowen 46th Annual Health Care Conference
◆Oral PresentationPresentation
Oppenheimer 36th Annual Healthcare Life Sciences Conference Fireside Chat
◆Oral PresentationPresentation
Guggenheim Securities Emerging Outlook: Biotech Summit Fireside Chat
◆Poster PresentationPalazestrantPresentation
Trial-in-progress poster for Phase 3 OPERA-02 trial of palazestrant plus ribociclib at SABCS 2025
ER+/HER2- advanced or metastatic breast cancersource ↗
◆Oral PresentationPresentation
Olema Oncology to participate in fireside chat at 8th Annual Evercore Healthcare Conference
▼Equity OfferingCorporate
Closing of $218.5 million public offering of common stock with full exercise of underwriters' option
▼Equity OfferingCorporate
Pricing of $190M public offering of common stock at $19.00 per share
◆Oral PresentationPresentation
Guggenheim 2nd Annual Healthcare Innovation Conference Fireside Chat
◆Poster PresentationPalazestrantPresentation
Poster presentation of updated data from Phase 1b/2 study of palazestrant plus ribociclib at ESMO 2025
ER+/HER2- advanced or metastatic breast cancersource ↗
▲Partnership / LicensePalazestrantCorporate
Clinical trial collaboration and supply agreement with Pfizer for palazestrant plus atirmociclib
ER+/HER2- metastatic breast cancersource ↗
▲Dose Finding UpdatePalazestrantTrial
Selected 90 mg once-daily palazestrant for Part 2 of OPERA-01
ER+/HER2- metastatic breast cancersource ↗
◆Trial InitiationPalazestrantTrial
OPERA-02 ribociclib combination trial anticipated to initiate this quarter
ER+/HER2- metastatic breast cancersource ↗
▲Oral PresentationPalazestrantPresentation
Presentation of data at ESMO 2025
ER+/HER2- metastatic breast cancersource ↗
▲Partnership / LicensePalazestrantCorporate
Clinical trial agreement with Pfizer to combine palazestrant with atirmociclib
ER+/HER2- metastatic breast cancersource ↗
▲First Patient DosedOP-3136Trial
Phase 1/2 study of OP-3136 expanded into combinations with fulvestrant and palazestrant
ER+ breast cancersource ↗
Past FDA Catalysts and PDUFA Decisions
How OLMA actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2025-04-28 | OP-3136 (selective KAT6 inhibitor) | Pre-clinical data readout | Pre-clinical |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
C47 / 100
Pipeline Score
$346M
Pipeline Value
Overvalued
Valuation Signal
3
Drugs Scored
0.5x
rNPV / MCap
Top 24%
Micro Cap(rank 159 of 660)
Percentile Rank
Olema Pharmaceuticals, Inc. carries a moderate pipeline score (47/100), with $865M risk-adjusted pipeline value, led by Palazestrant in Metastatic Breast Cancer (Phase 1).
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Palazestrant Small moleculeNCT05266105 | Breast Cancer | Phase 3 | ACTIVE NOT_RECRUITING | 1,570 | Mar 1, 2026 |
Clinical Trial Results
Readouts, endpoints and source filings for every OLMA program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| OP-3136 | advanced solid tumors | Phase 1 | 2026-05-22 | over two-thirds of patients showing tumor size reductionsRead More | Olema Oncology Announces Encouraging Initial Clinical Data from the Phase 1 Study of OP-3136, a KAT6 Inhibitor, at 2026 ASCO Annual MeetingRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Harmon CyrusDirector | Sell | -12,500 702,770 held | $11.71 | 07/24/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in OLMA
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Paradigm Biocapital Advisors LP | 2 % (-16.7 %) | 108.47 M | 8.67 M | 8.1% ( 650.00 K) |
OLMA Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2027-01-15 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How OLMA ranks across every disease it competes in
Competitive Position is a premium feature
See how OLMA ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialOLMA News
OLMAOlema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Olema Oncology announced the grant of stock options to six new employees, totaling 235,950 shares. This move, approved by the Compensation Committee, aligns with Nasdaq Listing Rule 5635(c)(4) and aims to incentivize new hires. The options will vest over four years, supporting the company's growth and commitment to breast cancer treatment.
Read more →OLMAOlema Oncology to Participate in Upcoming Investor Conferences
Olema Oncology has announced its participation in several upcoming investor conferences, including the Citi 2026 Biopharma Back to School Conference and the Morgan Stanley 24th Annual Global Healthcare Conference. The company is focused on developing targeted therapies for breast cancer, with its lead candidate, palazestrant, in Phase 3 trials. Live webcasts of the events will be available on their investor relations website.
Read more →OLMAOlema Oncology Appoints Jason O’Byrne as Chief Financial Officer
Olema Oncology has appointed Jason O'Byrne as Chief Financial Officer, a move seen as crucial as the company prepares for significant milestones, including pivotal data from OPERA-01 and its first potential commercial launch. O'Byrne brings over two decades of experience in finance and operations within the biotech sector, which will support Olema's transformation into a fully integrated oncology company. He expressed enthusiasm about contributing to the company's mission to improve outcomes for breast cancer patients.
Read more →OLMA▼ -12.6%on this newsshared move
Olema Oncology Reports Second Quarter 2026 Financial and Operating Results
Olema Oncology has reported its financial and operational results for the second quarter of 2026. The company has completed enrollment in the pivotal Phase 3 OPERA-01 trial, with top-line data anticipated in early 2027. Additionally, initial Phase 1 clinical data for OP-3136 was presented at the 2026 ASCO Annual Meeting, and a collaboration with Bayer has been established.
Read more →OLMAGuida Al Login Su LuckyNiki E Soluzione Ai Problemi Di Accesso
The article provides a comprehensive guide on accessing LuckyNiki and troubleshooting common login issues. It outlines the standard login procedure, including password recovery steps and account verification requirements. Additionally, it emphasizes the importance of security measures and offers guidance on contacting customer support for unresolved problems. Overall, it aims to enhance the user experience on the platform.
Read more →OLMABetfirst Login Troubleshooting For Users In The Netherlands
The article offers a detailed guide for users in the Netherlands facing login issues on Betfirst. It outlines common problems such as forgotten passwords and account blocks, providing step-by-step solutions. Emphasis is placed on the importance of account verification and security measures to ensure a smooth gaming experience. Users are encouraged to contact customer support for unresolved issues.
Read more →OLMA5Gringos Registration Steps For Players In Norway
The article outlines the registration process for 5Gringos, an online casino in Norway. It highlights the user-friendly interface, security measures, and the importance of selecting a welcome bonus. Players are guided through the steps of account creation, verification, and the available payment methods. The extensive game library and ongoing promotions are also emphasized.
Read more →OLMAResolving Cashpot Login Issues For Dutch Players
The article addresses common login issues faced by Dutch players on the Cashpot platform, offering practical troubleshooting steps. It highlights problems such as forgotten passwords, browser-related issues, and the importance of account verification. Players are guided on how to reset passwords and contact customer support if issues persist. The article aims to help users regain access swiftly and securely.
Read more →OLMASpinshouse Login Troubleshooting For Netherlands Players
The article offers a detailed guide for Dutch players experiencing login issues at Spinshouse. It outlines common problems such as forgotten passwords and account verification hurdles, providing step-by-step troubleshooting tips. The piece emphasizes the importance of customer support and offers advice on preparing for assistance. Overall, it aims to help players regain access to their accounts efficiently.
Read more →OLMACaxino Deposits And Withdrawals In The Netherlands: Supported Payment Methods And Fees
Caxino Casino in the Netherlands provides a user-friendly banking experience with various deposit and withdrawal options. Players can deposit funds instantly using popular methods like credit cards and e-wallets, with a minimum deposit of €10. Withdrawals are processed efficiently, especially through e-wallets, and the casino does not charge transaction fees, ensuring a secure and accessible gaming environment.
Read more →OLMAResolving Gamdom Login And Verification Issues In The UK
The article discusses the challenges UK players face when accessing Gamdom, an online casino. Due to its licensing under the Government of Curaçao, Gamdom cannot legally operate in the UK, leading to restricted access. Common login issues, KYC verification processes, and security practices are also outlined to help users navigate these challenges.
Read more →OLMACosta Bingo Pros And Cons For Austria: Games, Bonuses, And Payout Speed
Costa Bingo offers a vibrant platform for Austrian players, featuring a wide range of bingo and slot games. The site is regulated by the UK Gambling Commission, ensuring a secure gaming environment. However, players should be aware of currency conversion issues and promotional terms that cater primarily to the UK market. Overall, Costa Bingo provides a mix of advantages and drawbacks for its Austrian audience.
Read more →OLMAUnderstanding The Greenluck Withdrawal Pending Meaning
The article explains the 'withdrawal pending' status at Greenluck, detailing its importance in the cashout process. It emphasizes that this phase is crucial for security and verification, ensuring compliance with regulations. The article also outlines the withdrawal process, common reasons for pending status, and tips to expedite the process, highlighting the role of KYC and AML protocols.
Read more →OLMAOlema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - June 2, 2026
Olema Pharmaceuticals announced the granting of stock options to six new employees, totaling 176,150 shares, effective June 1, 2026. This move is part of the company's 2022 Inducement Plan and complies with Nasdaq Listing Rule 5635(c)(4). The stock options will vest over four years and have an exercise price of $12.71 per share.
Read more →OLMAOlema Oncology Announces Clinical Trial Collaboration and Supply Agreement with Bayer to Evaluate OP-3136 in Combination with NUBEQA (darolutamide) in Metastatic Castration-Resistant Prostate Cancer
Olema Oncology has announced a clinical trial collaboration with Bayer to evaluate OP-3136 in combination with NUBEQA for metastatic castration-resistant prostate cancer. This Phase 1b/2 study will include approximately 36 patients and aims to assess safety, tolerability, and preliminary anti-tumor activity. This agreement is significant as it represents the first clinical trial for OP-3136 in a combination scenario, expanding its potential therapeutic applications in oncology. Initial clinical data from a separate Phase 1 study of OP-3136 will be presented at the upcoming ASCO Annual Meeting.
Read more →OLMAOlema Oncology Announces Encouraging Initial Clinical Data from the Phase 1 Study of OP-3136, a KAT6 Inhibitor, at 2026 ASCO Annual Meeting
Olema Oncology announced preliminary clinical data from the Phase 1 study of OP-3136, a KAT6 inhibitor, showing promising anti-tumor activity and acceptable tolerability. The data will be presented at the ASCO Annual Meeting on May 30, 2026. The study includes patients with advanced breast cancer, prostate cancer, and lung cancer, with over two-thirds of patients showing tumor size reductions.
Read more →OLMA▲ +6.6%on this newsshared move
Olema Oncology to Participate in Upcoming Investor Conferences - May 19, 2026
Olema Oncology has announced its participation in several upcoming investor conferences, including the TD Cowen 7th Annual Oncology Innovation Summit and the Jefferies Global Healthcare Conference. The company is focused on developing targeted therapies for breast cancer and is advancing its lead product candidate, palazestrant, in Phase 3 trials. Additionally, Olema is developing another candidate, OP-3136, in a Phase 1 study.
Read more →About Olema Pharmaceuticals, Inc.
Headquarters780 BRANNAN STREET, SAN FRANCISCO, CA, 94103
BIOPHARMAWATCH ELITE PLUS
Trade the next OLMA catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime